198 related articles for article (PubMed ID: 27531416)
41. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
Bukh J
J Hepatol; 2016 Oct; 65(1 Suppl):S2-S21. PubMed ID: 27641985
[TBL] [Abstract][Full Text] [Related]
42. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
[TBL] [Abstract][Full Text] [Related]
43. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity".
Gane EJ; Agarwal K
Am J Transplant; 2014 May; 14(5):994-1002. PubMed ID: 24730431
[TBL] [Abstract][Full Text] [Related]
44. How Current Direct-Acting Antiviral and Novel Cell Culture Systems for HCV are Shaping Therapy and Molecular Diagnosis of Chronic HCV Infection?
Maggi F; Focosi D; Pistello M
Curr Drug Targets; 2017; 18(7):811-825. PubMed ID: 26245474
[TBL] [Abstract][Full Text] [Related]
45. Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization.
Deest M; Westhaus S; Steinmann E; Manns MP; von Hahn T; Ciesek S
Antiviral Res; 2014 Jan; 101():37-44. PubMed ID: 24211330
[TBL] [Abstract][Full Text] [Related]
46. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
J Virol; 2019 May; 93(10):. PubMed ID: 30842319
[TBL] [Abstract][Full Text] [Related]
47. Patterns of longitudinal change in hepatitis C virus neutralization titers correlate with the outcome of peginterferon and ribavirin combination therapy.
Lin J; Wang W; Xu Y; Di Bisceglie AM; Fan X
J Med Virol; 2015 May; 87(5):821-8. PubMed ID: 25652546
[TBL] [Abstract][Full Text] [Related]
48. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
Rafique S; Idrees M; Ali A; Iqbal M
Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
[TBL] [Abstract][Full Text] [Related]
49. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.
Vercauteren K; Van Den Eede N; Mesalam AA; Belouzard S; Catanese MT; Bankwitz D; Wong-Staal F; Cortese R; Dubuisson J; Rice CM; Pietschmann T; Leroux-Roels G; Nicosia A; Meuleman P
Hepatology; 2014 Nov; 60(5):1508-18. PubMed ID: 24797654
[TBL] [Abstract][Full Text] [Related]
50. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK
Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110
[TBL] [Abstract][Full Text] [Related]
51. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.
Lawitz EJ; O'Riordan WD; Asatryan A; Freilich BL; Box TD; Overcash JS; Lovell S; Ng TI; Liu W; Campbell A; Lin CW; Yao B; Kort J
Antimicrob Agents Chemother; 2015 Dec; 60(3):1546-55. PubMed ID: 26711747
[TBL] [Abstract][Full Text] [Related]
52. Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies.
Fauvelle C; Felmlee DJ; Crouchet E; Lee J; Heydmann L; Lefèvre M; Magri A; Hiet MS; Fofana I; Habersetzer F; Foung SK; Milne R; Patel AH; Vercauteren K; Meuleman P; Zeisel MB; Bartenschlager R; Schuster C; Baumert TF
Gastroenterology; 2016 Jan; 150(1):206-217.e4. PubMed ID: 26404951
[TBL] [Abstract][Full Text] [Related]
53. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans.
Law JL; Chen C; Wong J; Hockman D; Santer DM; Frey SE; Belshe RB; Wakita T; Bukh J; Jones CT; Rice CM; Abrignani S; Tyrrell DL; Houghton M
PLoS One; 2013; 8(3):e59776. PubMed ID: 23527266
[TBL] [Abstract][Full Text] [Related]
54. Clinical impact of hepatitis B and C virus envelope glycoproteins.
Jeulin H; Velay A; Murray J; Schvoerer E
World J Gastroenterol; 2013 Feb; 19(5):654-64. PubMed ID: 23429668
[TBL] [Abstract][Full Text] [Related]
55. Establishment of human clones producing neutralizing human monoclonal antibodies to the envelope E1/E2 protein of hepatitis C virus by EBV immortalization of immune CD22⁺ B cells.
Tabll A; El Abd Y; El Din NG; El Shenawy R; Abdelhafez TH; El Awady M; El-Mohamady H; Viazov S
Hum Antibodies; 2013; 22(3-4):55-65. PubMed ID: 24961863
[TBL] [Abstract][Full Text] [Related]
56. Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.
Pedersen J; Jensen TB; Carlsen TH; Schønning K; Christensen PB; Laursen AL; Krarup H; Bukh J; Weis N
PLoS One; 2013; 8(5):e62674. PubMed ID: 23667506
[TBL] [Abstract][Full Text] [Related]
57. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.
Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487284
[TBL] [Abstract][Full Text] [Related]
58. Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis.
Liu J; Ma B; Cao W; Li M; Bramer WM; Peppelenbosch MP; Pan Q
Transpl Infect Dis; 2019 Apr; 21(2):e13047. PubMed ID: 30615227
[TBL] [Abstract][Full Text] [Related]
59. Griffithsin has antiviral activity against hepatitis C virus.
Meuleman P; Albecka A; Belouzard S; Vercauteren K; Verhoye L; Wychowski C; Leroux-Roels G; Palmer KE; Dubuisson J
Antimicrob Agents Chemother; 2011 Nov; 55(11):5159-67. PubMed ID: 21896910
[TBL] [Abstract][Full Text] [Related]
60. Hepatitis C and liver transplantation.
Martini S
Minerva Gastroenterol Dietol; 2018 Jun; 64(2):158-169. PubMed ID: 28948755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
